Head & Neck Cancer Antibodies
Head and neck cancers are rare diagnosed cancers in the United States, with about 2.5% of all new cancer cases classified as oral cavity and pharynx, contributingapprox. 1.4% of cancer deaths yearly. As of 2011, there were approximately 282,000 people living with head and neck cancers in the United States. Those diagnosed with head and neck cancers have a 5 year survival rate of 62.7%. Over the last 10 years, both the new cancer case rate and the death rate have been stable. Biocare Medical is proud to offer key pancreatic and gall bladder antibodies that may aid in the identification of their respective proteins by IHC in FFPE tissues.
SEER Cancer Statistics Factsheets: Oral Cavity and Pharynx Cancer. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/oralcav.html